Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atea Pharmaceuticals (AVIR) Income from Continuing Operations (2020 - 2022)

Historic Income from Continuing Operations for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$34.4 million.

  • Atea Pharmaceuticals' Income from Continuing Operations fell 12939.5% to -$34.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$115.9 million, marking a year-over-year decrease of 19564.24%. This contributed to the annual value of -$168.4 million for FY2024, which is 2385.26% down from last year.
  • As of Q4 2022, Atea Pharmaceuticals' Income from Continuing Operations stood at -$34.4 million, which was down 12939.5% from -$8.1 million recorded in Q3 2022.
  • Over the past 5 years, Atea Pharmaceuticals' Income from Continuing Operations peaked at $117.1 million during Q4 2021, and registered a low of -$42.1 million during Q1 2022.
  • Its 3-year average for Income from Continuing Operations is -$152545.5, with a median of -$10.0 million in 2020.
  • Per our database at Business Quant, Atea Pharmaceuticals' Income from Continuing Operations skyrocketed by 46706.04% in 2021 and then crashed by 213606.24% in 2022.
  • Atea Pharmaceuticals' Income from Continuing Operations (Quarter) stood at $20.7 million in 2020, then surged by 467.06% to $117.1 million in 2021, then crashed by 129.4% to -$34.4 million in 2022.
  • Its Income from Continuing Operations was -$34.4 million in Q4 2022, compared to -$8.1 million in Q3 2022 and -$31.3 million in Q2 2022.